This study investigates the potential of Mimosa pudica, known as chuimui or lajwanti in Hindi, as a
herbal remedy for anxiety and depression. The plant is recognized for its diverse pharmacological
activities, encompassing analgesic, antidiarrheal, anti-inflammatory, hepatoprotective, antiasthmatic,
anti-ulcer, and antioxidant properties. The emphasis on its antidepressant and anxiolytic activity
positions it as a promising candidate for mental health treatment, with anticipated minimal side effects
compared to synthetic agents. The study also explores pre-formulation considerations, with a specific
emphasis on determining the ideal concentration of noacetylated gellan gum for in-situ gelation.
Preliminary investigations involve qualitative phytochemical screening of Mimosa Pudica extract by
cold maceration process, revealing the presence of bioactive components such as terpenoids,
flavonoids, glycosides, alkaloids, quinines, phenols, tannins, and saponins. These components are
known for their potential in modulating neurotransmission and exhibiting anxiolytic effects. The
research fine-tunes the concentration of deacetylated gellan gum for gelation using simulated nasal
fluid, with the objective of achieving gelation with minimal viscosity. Compatibility studies using
Fourier-transform infrared spectroscopy (FTIR) confirm the absence of significant interactions
between the drug and polymer. Additionally, differential scanning calorimetry (DSC) provides
insights into the thermal behaviour of the pure drug and the drug-polymer complex. Overall, thiscomprehensive investigation anticipates inspiring advanced research into the manifold benefits of
Mimosa pudica, particularly in the realm of mental health treatment, and lays the foundation for
potential herbal formulations with reduced side effects.
Keywords: Anxiolytic, Antidepressant, Intranasal, Mucoadhesive, Herbal formulations, Treatment
Publication date: 01/05/2024
https://ijbpas.com/pdf/2024/May/MS_IJBPAS_2024_8831.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.5.8831
